Revelation Biosciences (REVB) Cash & Equivalents (2020 - 2026)

Revelation Biosciences (REVB) has reported Cash & Equivalents for 6 consecutive years, with $10.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 64.64% year-over-year to $10.7 million; the TTM figure through Dec 2025 stood at $10.7 million (up 64.64% YoY), while the FY2025 annual figure was $10.7 million, up 64.64% from the prior year.
• Cash & Equivalents retreated to $10.7 million in Q4 2025 per REVB's latest filing, from $12.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $17.7 million in Q1 2023 and bottomed at $1.3 million in Q4 2021.
• Historically, Cash & Equivalents has averaged $9.1 million across 5 years, with a median of $7.2 million in 2022.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 10763.55% — and 2025, when it tumbled 74.57%.
• Revelation Biosciences' Cash & Equivalents stood at $1.3 million in 2021, then surged by 312.09% to $5.3 million in 2022, then soared by 128.28% to $12.0 million in 2023, then sank by 45.8% to $6.5 million in 2024, then soared by 64.64% to $10.7 million in 2025.
• Business Quant data shows REVB's Cash & Equivalents at $10.7 million in Q4 2025, $12.7 million in Q3 2025, and $5.2 million in Q2 2025.